8 ms·
This has a very simple fix, and is a fix that would appeal to Donald Trump: Require that pharmaceutical companies do not charge Americans any more for their dr
by RcouF1uZ4gsC 10y ago
This has a very simple fix, and is a fix that would appeal to Donald Trump:
Require that pharmaceutical companies do not charge Americans any more for their drugs than what they charge any developed country.
This lets other countries do the dirty work of negotiating prices while reaping the benefits for the US. In addition, it goes along with his whole America is getting screwed narrative - ie that other companies are taking advantage of the fact that American markets pay for the drug developments, and other countries reap benefits of cheap drugs and that he would put America back on equal footing.
EDIT: Thanks for the great comments. To ease with the concern about hurting the very poor countries, we could substitute "developed country" with "OECD country" (http://www.oecd.org/about/membersandpartners/list-oecd-member-countries.htm http://www.oecd.org/about/membersandpartners/list-oecd-membe... which are relatively rich countries).
- prostoalex 10y agoCan't the manufacturers still inflate list prices by introducing heavy rebates?
- pascalxus 10y agothis sounds like a good start.
- frgtpsswrdlame 10y agoWhy would that appeal to Donald Trump? It would hurt the profits of the drug industry in America which will cost jobs, pharma execs will tell him how bad this is for America and how harmful it is to drug R&D, etc etc. Donald Trump may have campaigned as a negotiator for the common man but he identifies with CEOs, anything that hurts them is not something that appeals to him.
- dv_dt 10y agoThe high price of medical care costs lives as well as jobs in other industries...
- frgtpsswrdlame 10y agoThat didn't stop him from trying to repeal Obamacare. I personally think we should institute drug price controls for many reasons including that one but I'm not sure why we are thinking that Donald Trump is going to do it.
- dv_dt 10y agoI don't know why Donald Trump does anything. But, I do think he's is of an unknown position in this particular area - so given that we have a problem in the US, and that Trump maybe doesn't have a defined position on the issue, it doesn't hurt to chase the possibility. (On the other hand if I'm just guessing with low-data: the chance does seems low).
- throwawaydp535 10y agoGiven that Obamacare insurance premiums are spiraling out of control, it's unclear why you're holding that up as an example of affordable healthcare.
- RcouF1uZ4gsC 10y agoThis may not actually hurt the profits of the drug industry, because they would probably renegotiate their prices with the other countries. Right now, as long as the cost of what they charge to country is basically their marginal cost of production, they don't have much incentive to oppose the negotiation. Now, they can say that because they have to charge the same to the US, the other countries will have to pay more, or not get the drug. Thus, this has the potential to be revenue neutral for the drug companies while spreading out the cost more fairly
- throwawaydp535 10y ago> Donald Trump may have campaigned as a negotiator for the common man but he identifies with CEOs, anything that hurts them is not something that appeals to him. Do you have any primary sources you can link to prove this assertion?
- white-flame 10y agoI think he means it would appeal to his political narrative of Americans being caught in a bunch of "bad deals" internationally.
- crack-the-code 10y agoWhat about the edge cases? If I understood you correctly, the poorest developed countries dictate the pricing.
- maxerickson 10y agoDepends on if it is profitable to sell them drugs in that world. If it isn't profitable, those countries either mostly do without or violate trade agreements (ignoring patents and the like).
- harryh 10y agoThis is not a great fix. Almost all companies (not just drug companies) routinely find ways to segment the market into different groups with different abilities to pay and then charge different prices for very similar products. That is the profit (or future research budget) maximizing strategy. The US is richer. It should be paying more. How much more is debatable.
- RcouF1uZ4gsC 10y agoThe US is richer and should be paying more than say Kenya. However, you would be hard-pressed to explain why the US should be paying more than say Denmark or Sweden or Germany?
- harryh 10y agoThe US is 8% richer than Denmark, 12% richer than Sweden and 40% richer than Germany on a per capita basis. https://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal)_per_capita https://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nomi... If you had said Luxembourg, Switzerland & Norway I would have agreed with you. That's only about 14 million people though.
- hfourm 10y agoHe still makes a point if for example country A is 8% poorer yet paying 40% less.
- harryh 10y agoIt's not obvious to me that expenditures on drugs should be a fixed % of one's income. It certainly seems like the % rises as people get richer.
- doktrin 10y ago> The US is 8% richer than Denmark, 12% richer than Sweden and 40% richer than Germany on a per capita basis. This seems to ignore the obvious discrepancies between income inequality in the US vs. Sweden & Germany. Our Gini coefficient is higher than both, as is our poverty rate. Our high GDP masks the fact that our world's-highest drug prices have a disproportionately negative effect on our poorest citizens.
- refurb 10y agoThere are a lot of problems with reference pricing. First off, if country A (300M people) references country B (30M people), then the drug company can simply chose not to launch the drug in country B if that reference price is too low. Second, drug companies can modify their launch sequence (this already happens today) so that they launch in the referenced countries after the price is set in the country doing the referencing. Third, this may actually push up the prices in other countries. This actually happened with Medicare Part B reimbursement back in the 1990s. Drug companies were offering big discounts to some private plans. Medicare said they wanted a piece of that, so they started calculating ASP (average selling price). Pretty quickly those other discounts disappeared and ASP got pushed way up and the gov't ended up with a fraction of the discounts they thought they'd get.
- frgtpsswrdlame 10y agoWhat price control method would you advocate for?
- quest88 10y agoFixing the patent system so generics can come to market faster. I'm not sure how.
- kgwgk 10y agoShortening the period of exclusivity could result in higher prices and less drugs being developed. There is no magic bullet.
- 8ytecoder 10y agoOn Evergreening: https://www.techdirt.com/articles/20130401/09233022536/indian-supreme-court-rejects-evergreening-pharma-patents.shtml https://www.techdirt.com/articles/20130401/09233022536/india... On forcing a license: http://www.nytimes.com/2012/03/13/business/global/india-overrules-bayer-allowing-generic-drug.html http://www.nytimes.com/2012/03/13/business/global/india-over... These may or may not work in a country like USA - due to its politics and "principles".
- Symmetry 10y agoAnd the Clinton Foundation's big victory was in getting drug companies to sell anti-HIV drugs in the third world for far lower prices than they would go for in wealthier countries. So I imagine the idea of ending that would be appealing to Trump.
- andmarios 10y agoBut isn't free market, unregulated prices, etc the mandate of US? I don't judge, just making a remark.
- white-flame 10y agoIt's not a free market if you're not allowed to import from cheaper suppliers elsewhere, so that's already broken.
- rayiner 10y agoPermitting imports also undermines the market if it extends the scope of the market to include areas where government intervention (e.g. aggressive negotiation by national health systems) drives prices below efficient levels.
- ThomPete 10y agoBut then at least as a company you know that.
- koolba 10y agoA free market requires price discovery. That's sorely lacking for the majority of the US healthcare industry. Doesn't matter if it's a pill, a check up, or an x-ray, good luck figuring out what it's going to cost you in advance.
- joe_the_user 10y agoOf course there's no simple fix. US health reform has been attempted based on series of simple fixes with all the best-seeming ones already exhausted over the twenty or thirty years it's been tried. And the entities profiting (enormously) from US health care have become champions, geniuses at dodging all the simple fixes. Of course you can't force companies to sell for the same prices elsewhere unless you had no regulation on drug imports and that would discard the whole regulation process effectively, blah, blah. Companies could just label the drugs they sold in different countries differently or even mix them differently (there's already re-mixing for patent and other purposes, etc). As noted in the article, the countries with lower drug prices do real, good regulation. To do that here, you'd need to take on regulatory capture and so-forth, a not at all simple matter.
- entee 10y agoYou're totally right, this is a hugely complex matter. However, it's not so simple to just relabel the drug, after all to a first approximation a drug is primarily an active ingredient and secondarily a delivery mechanism. You can patent one, the other or both together. There's definitely remixing, reformulation etc. for patent purposes, but it's not always that trivial to do. Re. regulatory capture, I don't know if the FDA or regulatory capture thereof is that huge an issue. The chief advantage other countries have is the ability to say, "No." Medicare doesn't have that ability, and even if we were to allow CMS (the agency that administers Medicare/Medicaid) to negotiate for drug prices, it's not much of a negotiation if CMS can't say, "we're not buying it." Can you imagine the outrage in congress from people calling in and saying, "I need this drug and Medicare isn't paying for it."? I guess that's regulatory capture in some way, but damn is it more complicated than cozy agency-industry relations. A really great and sober take on drug pricing from someone who's been in the industry forever can be found here: http://blogs.sciencemag.org/pipeline/archives/2015/12/02/a-look-at-drug-pricing http://blogs.sciencemag.org/pipeline/archives/2015/12/02/a-l... EDIT: Typo s/companies/countries/
- maxerickson 10y agoMedicare drug plans do say no. There's even tools to find one that works best for a given patient. https://q1medicare.com/PartD-SearchPDPMedicarePartDDrugFinder.php https://q1medicare.com/PartD-SearchPDPMedicarePartDDrugFinde...
- godelski 10y agoWell we need competition for that to happen. So somehow you'd have to set something up where you would need to allow for the consumer to buy from other countries. Which sounds pretty difficult.
- jstelly 10y agoI like this idea but it is probably difficult to implement. Can't drug companies make slightly different versions of drugs and work around this kind of arrangement? In that case the US would get the "best" version of the drug since it's paying the most, but that's not the solution you want (e.g. lower prices) because it's fighting the fundamental fact that the US will pay more for the same drug. I'm not a drug expert so maybe there are some drugs where this is impossible or improbable. But this is pretty typical in other industries so I would expect the same thing to happen here if it became necessary.
- RcouF1uZ4gsC 10y agoI don't think they can get around it that easily because both the patent protections and the FDA approval are based on the "active ingredient" and delivery method and thus they cannot easily introduce a new variant without going to a lot of expense.
- voxic11 10y agoBut they already have to get their drugs certified independently in other countries so yes it costs more to introduce multiple varients to the US market but it does not cost much more to introduce different varients to multiple countries that require independent verification of the drugs anyways.
- deleted 10y ago[deleted]
- dodgedcactii 10y agolol at "appealing" to DT based on logic, reason, human decency, critical or sustained long-term thinking.
- mlindner 10y agoThis is just price controls and fails for every other reason that price controls fails elsewhere. It puts the cost of drugs well above the market rate for such drugs in that country and opens the door for local producers to simply undercut. The long term effect of is this is that US sellers will essentially become galapagos companies that only sell to the US and you effectively create two markets. The end state is exactly where we're at now but only with the US bearing even more of the cost.
- aanm1988 10y agoThat would be a damn hard thing to pass, and the drug companies would fight it tooth and nail. Look at what they did in California.
- oppositelock 10y agoThere's another potential simple fix. Remove the regulatory capture which enables this. Enforce anti-trust law against medical companies. Remove all re-importation laws, which are purely a result of their lobbying. Allow safe, competitive drugs from abroad into the US market without spending billions to get them past the FDA. We didn't get here by accident, it's due to years of medical companies lobbying to twist the law. Medical costs are now 1/5 of the US economy, that's a lot of vested interest in things not getting more efficient.
- ddxxdd 10y ago>Require that pharmaceutical companies do not charge Americans any more for their drugs than what they charge any developed country If i recall correctly, that has been part of Trumps platform for several months before the election. Or rather, allowing American customers to buy drugs overseas was part of his platform. And i remember that idea went before a congressional vote recently, with both republicans and democrats voting it down. On mobile, so sorry i cant provide links.